Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ponatinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

40 träffar

Bibliografisk träff 2014-02-19

Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.

Jin B, Ding K, Ding K, Pan J.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-13-0397

Bibliografisk träff 2014-02-18

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.

Gibbons DL, Pricl S, Posocco P, Laurini E, Fermeglia M, Sun H, Talpaz M, Donato N, Quintás-Cardama A.

Proc Natl Acad Sci U S A · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1073/pnas.1321173111

Bibliografisk träff 2014-01-28

Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.

Jin Y, Ding K, Ding K, Li H, Xue M, Shi X, Wang C, Pan J.

Mol Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1476-4598-13-17

Bibliografisk träff 2014-01-28

Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells.

Sun YL, Kumar P, Sodani K, Patel A, Pan Y, Baer MR, Chen ZS, Jiang WQ.

Oncol Rep · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.3892/or.2014.3002

Bibliografisk träff 2014-01-23

Ponatinib circumvents FGF2-driven resistance to imatinib in CML.

Författaruppgift saknas

Cancer Discov · news · DOI 10.1158/2159-8290.cd-rw2014-016

Bibliografisk träff 2014-01-09

Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.

Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Martinez J, Tyner JW, Wong M, Druker BJ.

Blood · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1182/blood-2013-07-518381

Bibliografisk träff 2014-01-06

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

Sadovnik I, Lierman E, Peter B, Herrmann H, Suppan V, Stefanzl G, Haas O, Lion T, Pickl W, Cools J, Vandenberghe P, Valent P.

Exp Hematol · clinical trial; research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.exphem.2013.12.007

Bibliografisk träff 2014-01-01

Ponatinib: a third-generation inhibitor for the treatment of CML.

Wehrle J, Pahl HL, von Bubnoff N.

Recent Results Cancer Res · review; journal article · DOI 10.1007/978-3-642-54490-3_5

Bibliografisk träff 2013-12-02

BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.

Buffa P, Romano C, Pandini A, Massimino M, Tirrò E, Di Raimondo F, Manzella L, Fraternali F, Vigneri PG.

FASEB J · research support, non-u.s. gov't; journal article · DOI 10.1096/fj.13-236992

Bibliografisk träff 2013-11-21

Ariad suspends ponatinib sales.

Författaruppgift saknas

Cancer Discov · journal article · DOI 10.1158/2159-8290.cd-nb2013-163